Innovent Biologics, Inc. (HKG:1801)

Innovent Biologics Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 5, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	144,541	59,956	69,333	51,403	70,547	115,098
Market Cap Growth	148.54%	-13.53%	34.88%	-27.14%	-38.71%	243.36%
Enterprise Value	137,790	54,283	63,850	44,899	59,352	109,367
Last Close Price	83.30	36.60	42.75	33.50	48.25	82.05
PS Ratio	11.55	5.98	10.14	9.98	13.46	25.21
PB Ratio	9.15	4.30	5.02	4.24	5.56	11.04
P/TBV Ratio	10.12	4.40	5.04	4.25	5.57	11.04
P/FCF Ratio	91.12	175.32	-	-	-	-
P/OCF Ratio	72.62	43.78	425.78	-	-	-
EV/Sales Ratio	11.01	5.41	9.34	8.72	11.33	23.96
EV/EBITDA Ratio	99.47	2126.28	-	-	-	-
EV/FCF Ratio	86.86	158.73	-	-	-	-
Debt / Equity Ratio	0.23	0.22	0.29	0.30	0.24	0.14
Debt / EBITDA Ratio	2.54	50.93	-	-	-	-
Debt / FCF Ratio	2.33	8.81	-	-	-	-
Net Debt / Equity Ratio	-0.43	-0.38	-0.59	-0.55	-0.63	-0.79
Net Debt / EBITDA Ratio	-4.73	-210.62	5.70	2.06	2.57	14.13
Net Debt / FCF Ratio	-4.26	-15.72	7.56	2.11	2.11	8.68
Asset Turnover	0.52	0.45	0.33	0.27	0.30	0.40
Inventory Turnover	2.94	2.69	1.51	1.00	1.19	1.45
Quick Ratio	2.25	2.08	2.68	2.78	3.27	5.85
Current Ratio	2.61	2.35	3.00	3.29	3.79	6.37
Return on Equity (ROE)	8.43%	-0.74%	-8.84%	-20.70%	-28.56%	-14.75%
Return on Assets (ROA)	2.65%	-0.82%	-5.12%	-11.54%	-12.04%	-3.65%
Return on Capital Employed (ROCE)	5.00%	-1.60%	-9.70%	-22.20%	-20.50%	-5.40%
Earnings Yield	0.86%	-0.17%	-1.63%	-4.79%	-4.75%	-1.03%
FCF Yield	1.10%	0.57%	-1.54%	-6.19%	-5.38%	-0.82%
Buyback Yield / Dilution	-3.74%	-4.35%	-4.67%	-2.37%	-7.27%	-15.23%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.